Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes

Twenty participants with end stage kidney disease (ESKD) and burnt-out diabetes, and 20 non-diabetic participants with ESKD will wear a continuous glucose monitoring (CGM) device for 10 days to see if the use of CGM is a better tool to assess glycemic control than glycosylated hemoglobin (HbA1c) in patients with ESKD on dialysis.

Inclusion Criteria:Dialysis treatment for more than 3 monthsHbA1c less than 6.5% at the first clinic visitWilling to wear a CGM for 10 daysExclusion Criteria:Have used insulin or any diabetes treatment during the last 3 monthsBe pregnant or plan to become pregnant during the studyKnown allergy to medical-grade adhesivesTaking acetaminophen (more than 1 gram every six hours) or hydroxyurea (may interfere with sensor membrane)Current or anticipated use of stress steroid doses (prednisone </= 5 mg or its equivalent is allowed)